Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H22N2O3 |
Molecular Weight | 266.3361 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
InChI
InChIKey=METKIMKYRPQLGS-UHFFFAOYSA-N
InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
Molecular Formula | C14H22N2O3 |
Molecular Weight | 266.3361 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:03:17 UTC 2023
by
admin
on
Sat Dec 16 18:03:17 UTC 2023
|
Record UNII |
50VV3VW0TI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC07CB53
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
LIVERTOX |
NBK548379
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-ATC |
C07CB53
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-VATC |
QC07CB03
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-ATC |
C07BB03
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-ATC |
C07DB01
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-ATC |
C07CB03
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
NDF-RT |
N0000000161
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
NCI_THESAURUS |
C29576
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
NDF-RT |
N0000175556
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-VATC |
QC07AB03
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-VATC |
QC07BB03
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-ATC |
C07FB03
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-VATC |
QC07DB01
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-VATC |
QC07FB03
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
||
|
WHO-ATC |
C07AB03
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL24
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
55352
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
ATENOLOL
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
757832
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
50VV3VW0TI
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
3801
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
2904
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
249-451-7
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
548
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
1044403
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
29122-68-7
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
50VV3VW0TI
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
D001262
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
DB00335
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
1202
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | RxNorm | ||
|
m2120
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB05590MIG
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
C28836
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
Atenolol
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
2249
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
6526
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
100000091183
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
255
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
DTXSID2022628
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | |||
|
ATENOLOL
Created by
admin on Sat Dec 16 18:03:20 UTC 2023 , Edited by admin on Sat Dec 16 18:03:20 UTC 2023
|
PRIMARY | Description: A white or almost white powder. Solubility: Sparingly soluble in water; soluble in ethanol (~750 g/l) TS; slightly soluble in dichloromethane R. Category: Cardiovascular agent; β-adrenoreceptor blocking agent. Storage: Atenolol should be kept in a tightly closed container. Requirement: Atenolol contains not less than 99.0% and not more than 101.0% of C14H22N2O3, calculated with reference to the dried substance. |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
ENANTIOMER -> RACEMATE |
|
||
|
ENANTIOMER -> RACEMATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE LESS ACTIVE -> PARENT |
found to have only one tenth of the activity of atenolol
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
RENAL IMPAIRMENT: CREATINE CLEARANCE LESS THAN 15 mL/min/1.73 m(2 |
|
||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||